Cart
sales@molnova.com
BUR1
CAS No. 23000-46-6
BUR1( BUR-1 | BUR 1 | BMP upregulator 1 | BMP upregulator-1 )
Catalog No. M27759 CAS No. 23000-46-6
BUR1 is a Saccharomyces cerevisiae cyclin-dependent kinase (CDK) and is homologous to mammalian Cdk9, which functions in transcriptional elongation.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 302 | Get Quote |
|
| 10MG | 447 | Get Quote |
|
| 25MG | 714 | Get Quote |
|
| 50MG | 1017 | Get Quote |
|
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameBUR1
-
NoteResearch use only, not for human use.
-
Brief DescriptionBUR1 is a Saccharomyces cerevisiae cyclin-dependent kinase (CDK) and is homologous to mammalian Cdk9, which functions in transcriptional elongation.
-
DescriptionBUR1 is a Saccharomyces cerevisiae cyclin-dependent kinase (CDK) and is homologous to mammalian Cdk9, which functions in transcriptional elongation.
-
In Vitro——
-
In Vivo——
-
SynonymsBUR-1 | BUR 1 | BMP upregulator 1 | BMP upregulator-1
-
PathwayAngiogenesis
-
TargetCDK
-
RecptorSETD2
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number23000-46-6
-
Formula Weight279.347
-
Molecular FormulaC16H17N5
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC1CCN(CC1)c1ncnc2n(ncc12)-c1ccccc1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Jennifer Totman, et al. Pharmacologic Inhibition of the Histone Methyltransferase SETD2 with EZM0414 As a Novel Therapeutic Strategy in Relapsed or Refractory Multiple Myeloma and Diffuse Large B-cell Lymphoma.
molnova catalog
related products
-
BS-194
BS-194 is a potent, selective, orally bioactive CDK2 inhibitor with IC50 of 2.4 nM, displays 140-fold selectivity over CDK7 (IC50=378 nM); weakly inhibits CDK1, CDK5, CDK7, and CDK9 with IC50 of 30, 30, 250, and 90 nM.
-
CDK7 and 9 inhibitor...
A potent, selective transcriptional CDK inhibitor with Ki of 2.3 and 0.38 nM for CDK7 and CDK9, respectively; displays >30-fold selectivity over CDK1/2/4, inhibits VEGFR2 with IC50 of 180 nM in a panel of non-CDK kinases.
-
SR-4835
SR-4835 is a highly selective dual inhibitor of CDK12 and CDK13(CDK12: IC50=99 nM Kd=98 nM; CDK13: Kd=4.9 nM) which disables triple-negative breast cancer (TNBC) cells.
